---
title: "Allermi vs Dymista: Compounded vs FDA-Approved Combo"
description: Compounded multi-ingredient Rx (§503A) vs FDA-approved fixed-dose azelastine + fluticasone combo.
canonical: "https://allermi-site.vercel.app/allermi/allermi-vs-dymista/"
lastReviewed: "2026-04-28T00:00:00.000Z"
firstPublished: "2026-04-21T00:00:00.000Z"
primaryKeyword: allermi vs dymista
ymylTier: high
author:
  name: BestAllergyNasalSprays Editorial Team — Clinical Pharmacy
  credential: Editorial Pool
  sameAs: ["https://dailymed.nlm.nih.gov/", "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"]
medicalReviewer:
  name: BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology
  credential: Editorial Pool
  sameAs: ["https://www.aaaai.org/", "https://www.acaai.org/"]
citations: []
claims: [c-003, c-004, c-009, c-010, c-011, c-039, c-040, c-048, c-049, c-075, c-078]
---

## TL;DR

Dymista is an FDA-approved fixed-dose combination of azelastine + fluticasone propionate. Allermi is a §503A-compounded telehealth spray that can include up to 4 actives (azelastine + triamcinolone + ipratropium + micro-dose oxymetazoline). Dymista's finished product is FDA-approved; Allermi's compounded formula is not separately FDA-approved, but its individual ingredients are. Dymista requires a visit-based Rx; Allermi is telehealth-only.

import Claim from '../../components/Claim.astro';
import CitationList from '../../components/CitationList.astro';

<aside class="material-connection-disclosure" role="note" aria-label="Material connection disclosure">**Disclosure (FTC 16 CFR Part 255):** BestAllergyNasalSprays is owned and operated by Allermi, Inc. — the company behind Allermi nasal spray. This is a [material connection](/about/ownership/) between the publisher and a reviewed product. Allermi is ranked under the same public criteria as every other product. Read the full ownership and editorial-policy disclosure [here](/about/ownership/).</aside>

<Claim id="c-039">Dymista is an FDA-approved fixed-dose combination nasal spray containing azelastine HCl 137 mcg and fluticasone propionate 50 mcg per spray, indicated for seasonal allergic rhinitis in patients 6 and older</Claim> <Claim id="c-040">In a Phase III RCT (Carr 2012), the azelastine + fluticasone combination spray (MP29-02 / Dymista) produced significantly greater nasal-symptom relief than either agent alone or placebo in patients with moderate-to-severe seasonal allergic rhinitis</Claim> <Claim id="c-048">Combining azelastine and fluticasone propionate (whether co-administered or as the co-formulated product Dymista / MP29-02) produces greater allergic-rhinitis symptom relief than either agent alone, demonstrated in three Phase III RCTs in moderate-to-severe seasonal allergic rhinitis (n=3,398)</Claim> <Claim id="c-011">Each active ingredient in Allermi is individually FDA-approved for the treatment of rhinitis. Allermi formulations are prepared by a state-licensed compounding pharmacy under the federal Food, Drug, and Cosmetic Act (section 503A); compounded drug products themselves are not FDA-approved as fixed-dose combinations and are primarily overseen by state pharmacy boards, with FDA conducting surveillance and for-cause inspections</Claim> <Claim id="c-003">Ipratropium is an anticholinergic that blocks muscarinic receptors in the nasal lining to reduce glandular secretions, helping with runny nose. As a nasal spray, it acts locally in the nasal passages</Claim> <Claim id="c-004">In short-term randomized trials (up to 4 weeks), co-administering an intranasal corticosteroid with oxymetazoline has not produced rhinitis medicamentosa, and intranasal corticosteroids reverse oxymetazoline-induced tachyphylaxis once it develops; long-term safety beyond a few weeks has not been established in large randomized trials.</Claim> <Claim id="c-049">In a 28-day randomized double-blind multicenter trial (Kumar 2022, n=250), a once-daily fixed-dose combination of fluticasone furoate plus oxymetazoline produced a significantly greater reduction in Total Nasal Symptom Score and a higher rate of complete nasal-congestion relief than fluticasone furoate alone, with rates of post-stoppage rebound congestion that did not differ from the steroid-only arm.</Claim> <Claim id="c-075">Adding intranasal ipratropium to an intranasal corticosteroid is supported by randomized trial evidence (Dockhorn 1999) for additive benefit when rhinorrhea remains a predominant symptom on a corticosteroid alone</Claim> <Claim id="c-078">Dymista's cash price typically ranges from about $50 to $260 per month depending on the pharmacy, and is often substantially lower with insurance coverage or a GoodRx coupon</Claim> <Claim id="c-009">Allermi is not currently prescribed during pregnancy or breastfeeding</Claim> <Claim id="c-010">Allermi is currently available to eligible patients ages 13 and older across most US states</Claim>

<CitationList items={[
 { id: "1", title: "Carr 2012: Dymista RCT", url: "https://pubmed.ncbi.nlm.nih.gov/22418065/", publisher: "PubMed", year: 2012 }
]} />